Indirect comparison incorporating Real-World Evidence
Challenge
Significant uncertainty in the estimated survival for the comparator treatment:
- New innovative treatment option and no gold standard in this indication
- Comparator used in pivotal trial not available in Europe; high level of crossover to study drug (>70%)
Request
Estimate survival advantage compared to current clinical practice as per HTA requirements
Response
- Conducted indirect comparison and crossover adjustment
- Supervised analysis of real-world evidence (RWE) which provided an alternative source of comparator estimated survival
- Conceptualised new economic model in area with no precedence
